Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending November 11, 2008. The report details a specific corporate action regarding the repurchase and cancellation of the company's own ordinary shares.
Key Financial Metrics
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on share capital movements.
- Shares Repurchased: 350,000 ordinary shares of 25 pence each.
- Repurchase Price: 1,215.26 pence per share.
- Treasury Shares Held: 474,194,158 shares (representing 9.10% of total voting rights).
- Shares in Issue: 5,211,323,495 shares (excluding Treasury shares).
Material Changes
The primary material change reported is the reduction of the company's share capital through the cancellation of 350,000 shares purchased on November 11, 2008. This transaction was executed under authority granted by shareholders at the Annual General Meeting on May 21, 2008. Consequently, the number of shares in issue was adjusted to 5,211,323,495.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It is a compliance disclosure confirming conformity with the Financial Services Authority's Disclosure and Transparency Rules.
Key Facts for Investor Verification
- Verify the total number of shares in issue (5,211,323,495) for calculating ownership thresholds under Disclosure and Transparency Rules.
- Confirm the updated Treasury share count (474,194,158) and its impact on total voting rights (9.10%).
- Note that the repurchased shares were cancelled rather than held for future reissue.